Syncromune, Inc. Enters into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., Ltd., to Develop and Commercialize YH002 (OX40 Antibody) and Two Undisclosed Active Ingredients as Components of the Syncrovax™ Combination Immunotherapy Platform FORT LAUDERDALE, FL. and BEIJING, China, October 18, 2022 (BUSINESS WIRE) – Syncromune, Inc., a clinical...

Syncromune, Inc. to Present at the 2022 BIO CEO & Investor Conference Syncromune, Inc. to Present at the 2022 BIO CEO & Investor Conference FORT LAUDERDALE, FL., Feb. 11, 2022 (BUSINESS WIRE) -- Syncromune, Inc., a clinical stage biopharmaceutical company focused on the development of intratumoral immunotherapy announced today that...